New combo therapy for bulky tumors enters human testing

NCT ID NCT06349837

Recruiting now Disease control Sponsor: Sichuan University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a combination of low dose radiotherapy, focused radiation (SBRT), and the immunotherapy drug tislelizumab in people with large solid tumors that have not responded to standard treatments. The study aims to see if this approach is safe and tolerable. About 24 participants will be enrolled, and the main focus is on side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tislelizumab (a drug that helps the immune system fight cancer), low dose radiotherapy, and stereotactic ablative radiotherapy (focused radiation)
What this could lead to: If successful, this could point toward a new treatment option for people with large tumors that have not responded to standard therapy.
What could go wrong: This is a very early, small Phase 1 trial with only 24 participants, so results may not apply to everyone. The main goal is safety, not effectiveness, and there are risks from radiation and immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

West China Hospital, Sichuan University
RECRUITING

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.